RhumbLine Advisers
MLYS icon

RhumbLine Advisers’s Mineralys Therapeutics MLYS Stock Holding History

RhumbLine Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.8M Buy
71,660
+1,455
+2% +$39.6K ﹤0.01% 1953
2026
Q2 		$1.89M Buy
70,205
+12,761
+22% +$350K ﹤0.01% 1966
2026
Q1 		$1.56M Buy
57,444
+3,160
+6% +$92.7K ﹤0.01% 1987
2025
Q4 		$1.97M Sell
54,284
-1,007
-2% -$40.4K ﹤0.01% 1885
2025
Q3 		$2.1M Buy
55,291
+1,695
+3% +$36.7K ﹤0.01% 1885
2025
Q2 		$725K Buy
53,596
+14,235
+36% +$206K ﹤0.01% 2424
2025
Q1 		$625K Sell
39,361
-1,195
-3% -$13.7K ﹤0.01% 2424
2024
Q4 		$499K Buy
40,556
+695
+2% +$9.09K ﹤0.01% 2679
2024
Q3 		$483K Sell
39,861
-1,218
-3% -$14.7K ﹤0.01% 2720
2024
Q2 		$481K Buy
41,079
+18,519
+82% +$233K ﹤0.01% 2708
2024
Q1 		$291K Buy
22,560
+2,091
+10% +$25.8K ﹤0.01% 2994
2023
Q4 		$176K Buy
20,469
+3,295
+19% +$25.9K ﹤0.01% 3245
2023
Q3 		$163K Buy
17,174
+2,279
+15% +$29.7K ﹤0.01% 3262
2023
Q2 		$254K Buy
14,895
+3,935
+36% +$58.8K ﹤0.01% 3108
2023
Q1 		$172K Buy
+10,960
New +$184K ﹤0.01% 2769

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

RhumbLine Advisers's MLYS Position: Q3 2026 in Review

RhumbLine Advisers increased its Mineralys Therapeutics (MLYS) stake by 2.1% in Q3 2026, buying an estimated $39.6K and bringing the position to 71,660 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

RhumbLine Advisers first reported a position in MLYS in Q1 2023 and has held it in 15 quarters since. The position peaked at $2.1M in Q3 2025. 88 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • RhumbLine Advisers held 71,660 shares of Mineralys Therapeutics worth $1.8M as of Q3 2026.
  • RhumbLine Advisers bought 1,455 Mineralys Therapeutics shares in Q3 2026, an estimated $39.6K.
  • Mineralys Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1953 holding.
  • RhumbLine Advisers first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • RhumbLine Advisers's Mineralys Therapeutics position peaked at $2.1M in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.